Compare
Solid Biosciences Inc. vs DBV Technologies S.A. vs TScan Therapeutics, Inc. vs Agenus Inc
| Latest fiscal year | Solid Biosciences Inc. SLDB | DBV Technologies S.A. DBVT | TScan Therapeutics, Inc. TCRX | Agenus Inc AGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $5.64M | $10.32M | $114.20M |
| Revenue growth (YoY) | n/a | +35.8% | +266.7% | +10.4% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | -17.7% |
| Net margin | n/a | n/m | n/m | -2.7% |
| Net income | -$174.32M | -$146.95M | -$129.77M | -$3.08M |
| EPS (Diluted) | -$1.99 | -$1.05 | -$1.00 | $0.00 |
| Operating cash flow | -$156.29M | -$121.18M | -$135.32M | -$77.19M |
| Free cash flow | -$157.44M | -$121.71M | -$139.73M | -$77.20M |
| Cash & equivalents | $59.90M | $194.17M | $152.41M | $3.00M |
| Total assets | $232.54M | $233.72M | $228.79M | $226.80M |
| Total liabilities | $52.53M | $64.95M | $105.67M | n/a |
| Shareholders' equity | $180.01M | $168.77M | $123.12M | -$271.11M |
| Return on year-end equity | -96.8% | -87.1% | -105.4% | n/a |
| Shares outstanding | 78.97M | n/a | n/a | 35.32M |
Revenue, most recent five fiscal years
| Fiscal year | Solid Biosciences Inc. | DBV Technologies S.A. | TScan Therapeutics, Inc. | Agenus Inc |
|---|---|---|---|---|
| Latest | $8.09M Ended 2022-12-31 | $5.64M Ended 2025-12-31 | $10.32M Ended 2025-12-31 | $114.20M Ended 2025-12-31 |
| 1 year earlier | $13.62M Ended 2021-12-31 | $4.15M Ended 2024-12-31 | $2.82M Ended 2024-12-31 | $103.46M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2020-12-31 | $15.73M Ended 2023-12-31 | $21.05M Ended 2023-12-31 | $156.31M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2019-12-31 | $4.84M Ended 2022-12-31 | $13.54M Ended 2022-12-31 | $98.02M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2018-12-31 | $5.71M Ended 2021-12-31 | $10.14M Ended 2021-12-31 | $295.67M Ended 2021-12-31 |